It is important to recognize that guidelines evolve over time, and in the recently published ASCO—Society of Surgical Oncology Guidelines [23], the authors recommend that genetic testing of BRCA1 and BRCA2 should be offered to all patients with a previous history of breast cancer and without active disease diagnosed at 65 years or younger, as well as selectively to patients diagnosed after 65 years if the result will inform personal risk management and/or family risk assessment. This evidence concerns the gene BRCA2 and breast carcinoma.